Kymera Therapeutics, Inc. (KYMR)
- Previous Close
33.35 - Open
33.75 - Bid 33.30 x 200
- Ask 33.39 x 300
- Day's Range
33.22 - 34.13 - 52 Week Range
9.60 - 45.31 - Volume
447,088 - Avg. Volume
639,184 - Market Cap (intraday)
2.048B - Beta (5Y Monthly) 2.27
- PE Ratio (TTM)
-- - EPS (TTM)
-2.52 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
51.36
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
www.kymeratx.comRecent News: KYMR
Performance Overview: KYMR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KYMR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KYMR
Valuation Measures
Market Cap
2.05B
Enterprise Value
1.76B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
24.78
Price/Book (mrq)
5.18
Enterprise Value/Revenue
22.36
Enterprise Value/EBITDA
-12.27
Financial Highlights
Profitability and Income Statement
Profit Margin
-186.99%
Return on Assets (ttm)
-17.55%
Return on Equity (ttm)
-33.21%
Revenue (ttm)
78.59M
Net Income Avi to Common (ttm)
-146.96M
Diluted EPS (ttm)
-2.52
Balance Sheet and Cash Flow
Total Cash (mrq)
374.88M
Total Debt/Equity (mrq)
21.44%
Levered Free Cash Flow (ttm)
-97.62M
Research Analysis: KYMR
Company Insights: KYMR
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: KYMR
Daily – Vickers Top Buyers & Sellers for 11/07/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/01/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 05/10/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.